Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
07:00am, Thursday, 28'th May 2026
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapie
Relmada Therapeutics Q1 Earnings Call Highlights
10:06pm, Tuesday, 12'th May 2026
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladde
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
09:30pm, Tuesday, 12'th May 2026
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th May 2026
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
07:00am, Wednesday, 06'th May 2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapie
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
07:00am, Tuesday, 05'th May 2026
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapie
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
10:55am, Monday, 13'th Apr 2026
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
11:01am, Thursday, 02'nd Apr 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
10:56am, Thursday, 26'th Mar 2026
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Financial Contrast: Alseres Pharmaceuticals (OTCMKTS:ALSE) vs. Relmada Therapeutics (NASDAQ:RLMD)
01:10am, Wednesday, 25'th Mar 2026
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Alseres Pharmaceuticals (OTCMKTS:ALSE - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
10:12pm, Thursday, 19'th Mar 2026
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
04:01pm, Thursday, 19'th Mar 2026
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
RLMD Stock Surges 42% in a Week: Here's What You Should Know
02:06pm, Thursday, 12'th Mar 2026
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
07:00am, Thursday, 12'th Mar 2026
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therap
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
07:00pm, Monday, 09'th Mar 2026
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were
